What Should Be Learned From Repurposed Antivirals Against SARS-CoV-2?
Front Microbiol
.
2022 Feb 16:13:843587.
doi: 10.3389/fmicb.2022.843587.
eCollection 2022.
Author
Miguel Angel Martinez
1
Affiliation
1
IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain.
PMID:
35250956
PMCID:
PMC8889110
DOI:
10.3389/fmicb.2022.843587
No abstract available
Keywords:
SARS-CoV-2; antiviral; emerging viruses; repurposed drugs; virus therapy.